AUS
NZ
UK
CA
USA
IND
Highlights
- CMS Approval: FebriDx received a PLA code (0442U) with reimbursement set at US$41.38 per test, effective January 2025.
- Unique Diagnostic Tool: FebriDx distinguishes bacterial from non-bacterial infections, addressing antibiotic overprescription and resistance.
- Strategic Focus: Lumos aims to integrate FebriDx into clinical pathways and secure further reimbursement agreements with U.S. insurers.
Shares of Lumos Diagnostics (ASX:LDX) jumped 22.6% to 3.8 cents on 5 December 2024, following a major breakthrough in the company’s commercial efforts for its FebriDx point-of-care diagnostic test. The U.S. Centers for Medicare & Medicaid Services (CMS) Panel approved a reimbursement rate of US$41.38 per test for FebriDx, effective January 1, 2025.
Details of the Milestone
Lumos Diagnostics announced the approval of the FebriDx PLA code, issued by the American Medical Association, which will feature on the Clinical Lab Fee Schedule starting January 2025. This decision marks a significant step in the company’s efforts to make the diagnostic test more accessible to healthcare providers and patients.
The CMS-approved reimbursement rate is expected to drive adoption by enabling coverage through both government programs and private insurers. Lumos emphasized that this milestone will facilitate broader use of FebriDx, which has the unique ability to differentiate bacterial infections from viral ones at the point of care.
The Importance of FebriDx in Tackling Antibiotic Resistance
FebriDx’s diagnostic capabilities address a critical healthcare challenge: the overprescription of antibiotics. Most acute respiratory infections are viral and do not require antibiotics, yet they are prescribed in approximately 50% of cases. This misuse contributes significantly to antibiotic resistance, a pressing issue in the U.S. that causes an estimated 2.8 million illnesses and 35,000 deaths annually.
By helping healthcare providers make informed decisions about treatment, FebriDx has the potential to reduce unnecessary antibiotic prescriptions, improve patient outcomes, and combat resistance.
Next Steps for Lumos Diagnostics
Lumos plans to leverage the PLA code approval to expand FebriDx’s integration into U.S. healthcare systems. The company will:
- Work with U.S. private and government payers to establish reimbursement and coverage policies.
- Integrate FebriDx into clinical pathways and triage workflows.
- Pursue a Clinical Laboratory Improvement Amendments (CLIA) waiver label, further broadening its accessibility.
Lumos views the CMS approval as a critical enabler for FebriDx’s commercial success, paving the way for increased adoption across the U.S. healthcare market.
